Many of the trace amines-more correctly called biogenic amines- have been known for decades, but because of their tiny concentra- tions (0. 01-100 ng/g) in brain, it was only after the development of sophisticated analytical techniques (such as mass spectrometry) that they could be identified and quantitated in nervous tissue. There are now more than 20 of them and most are related to the catecholamines and 5-hydroxytryptamine both structurally and metabolically. Their pharmacological and physiological properties make them prime candidates for a transmitter or neuromodulator role and many of them elicit profound behavioral syndromes after injection--one of them, phenylethylamine, has even been referred to as nature's amphetamine. In the clinical sphere several have been shown to be involved in: Parkinsonism, schizophrenia, depression, agoraphobia, aggression, hyperkinesis, migraine, hypertensive crises, hypertyrosinemia, he- patic encephalopathy, epilepsy, and cystic fibrosis. Thus the research reported here on these intriguing "new" substances will be of great interest to psychiatrists, neurologists, biochemists, pharmacologists, physiologists, psychologists, behaviorists and indeed to all those working in the neurosciences and related fields today. ACKNOWLEDGMENTS This book is based on the proceedings of Trace Amines and the Neurosciences, a meeting held at the University of Alberta, Edmonton, July 19-21, 1983. This meeting was organized as a Satellite Meeting of the Ninth Meeting of the International Society for Neurochemistry, held in Vancouver, July 10-15, 1983. International organizers of the satellite meeting were Drs. A. A. Boulton (Saskatoon), W. G. Dewhurst (Edmonton), G. B. Baker (Edmonton), and M. Sandler (London).

Organisational Development in Healthcare introduces the practical ways in which change in health services can be promoted. It includes descriptions of all of the most important approaches to change currently being used in the NHS discussion of when they work best and details of the evidence of their impact. 'The interest in organisational development reflects a growing realisation that many of our previous managerial methods are inappropriate and that a new set of techniques and approaches are required. As this book points out creating a new set of jargon techniques and alchemy will surely mean that organisational development is as divorced from what clinicians do patients experience and the public expects as previous reform programmes. Change ideas such as case management for long term conditions that should directly appeal to what clinicians want to achieve could become yet another project done by management that will pass when the enthusiasm wanes and which totally alienates those it should most appeal to. This book provides a key guide to leaders trying to engage their staff in changing their organisations by bringing together theory and experience. This is important as too often theory is neglected and there is inadequate reflection on experience' Nigel Edwards in his Foreword 'An invaluable addition to every practising health manager's bookshelf. I hope you gain a great deal from reading this book and I hope it helps in the efforts that are underway to transform our National Health Service.' David Fillingham in his Foreword

Many of the trace amines-more correctly called biogenic amines- have been known for decades, but because of their tiny concentra- tions (0. 01-100 ng/g) in brain, it was only after the development of sophisticated analytical techniques (such as mass spectrometry) that they could be identified and quantitated in nervous tissue. There are now more than 20 of them and most are related to the catecholamines and 5-hydroxytryptamine both structurally and metabolically. Their pharmacological and physiological properties make them prime candidates for a transmitter or neuromodulator role and many of them elicit profound behavioral syndromes after injection--one of them, phenylethylamine, has even been referred to as nature's amphetamine. In the clinical sphere several have been shown to be involved in: Parkinsonism, schizophrenia, depression, agoraphobia, aggression, hyperkinesis, migraine, hypertensive crises, hypertyrosinemia, he- patic encephalopathy, epilepsy, and cystic fibrosis. Thus the research reported here on these intriguing "new" substances will be of great interest to psychiatrists, neurologists, biochemists, pharmacologists, physiologists, psychologists, behaviorists and indeed to all those working in the neurosciences and related fields today. ACKNOWLEDGMENTS This book is based on the proceedings of Trace Amines and the Neurosciences, a meeting held at the University of Alberta, Edmonton, July 19-21, 1983. This meeting was organized as a Satellite Meeting of the Ninth Meeting of the International Society for Neurochemistry, held in Vancouver, July 10-15, 1983. International organizers of the satellite meeting were Drs. A. A. Boulton (Saskatoon), W. G. Dewhurst (Edmonton), G. B. Baker (Edmonton), and M. Sandler (London).

A high proportion of drugs currently coming to market exert their action in the body by inhibiting a target enzyme involved in a particular body function or in a bacterium, protozoon, or virus causing an infection. This book extends the previous volume in providing a comprehensive coverage of< br> more recently recognized target enzymes and their known inhibitors and, within this framework of knowledge, demonstrates how the drug designer uses all available information to develop a specific therapeutic agent. Drug design is an interdisciplinary art; this text illustrates the pathway followed< br> from the initial design concept and synthesis of an inhibitor, through its in vitro and in vivo assessments, to clinical trial -- a process involving chemists, biochemists, pharmacologists, and clinicians.

The field of research in 5-hydroxytryptamine has exploded into furious activity over the past decade and nowhere have the implications been more far reaching than in psychiatry. Thanks largely to the introduction of radioligand binding techniques, a bewildering variety of 5-hydroxytryptamine receptors has been revealed, and powerful new families of centrally-active drugs have emerged. The importance of these new discoveries for psychiatric practice can hardly be exaggerated. To mention but one example, our understanding, and with it the treatment, of obsessive-compulsive disorder has been transformed in a very few years. The excitement continues, and almost daily, some important new insight, usually drug led, alters our whole perception of psychiatric illness. Due to this activity, the CINP chose 5-hydroxytryptamine and Psychiatry as the topic for its first President's Workshop. The CINP is an international neuropharmacological organization renowned for its massive, comprehensive, and prestigious biennial congress. It recently decided to complement these with a different type of gathering, a small brain-storming meeting, dominated by a free-flowing discussion. The record of this first President's Workshop is recorded here. The contributors were all hand-picked, and are active researchers with a distinguished track record. They have all contributed substantially to the burgeoning 5-hydroxytryptamine field. The free-ranging style of this volume and the many good ideas presented cannot fail to be of major interest to all who wish to keep abreast of this rapidly moving area of research.

Thirty per cent of all women and ten per cent of all men experience migraine. This crippling illness does not kill, but its high morbidity poses a massive economic problem and gives rise to considerable suffering. Its main manifestation, headache, is subjective, and there are no animal models. This makes traditional research approaches difficult, and has led to a variety of research strategies. In this study, leaders in migraine research present the numerous advances that have been made over the past two decades in our understanding of this disorder, and discuss in depth the position of migraine research today and the directions it will take in the future.

Interest in wine science has grown enormously over the last two decades as the health benefits of moderate wine consumption have become firmly established in preventing heart disease and been extended to stroke, cancer and dementia. The growth of molecular biology has allowed proper investigation of grapevine identity and lineage and led to improvements in the winemaking process.
This book explores the history and appreciation of wine, its early role as a medicine and modern evidence on how and why wine protects against disease. It also addresses genetic modification of the grapevine, long recognized as a natural process, and of the microbes involved in the making of wine. Pharmacologists, biochemists, epidemiologists, physicians, and public health officials will find this book not only a wealth of data, but also a fascinating read.

eBook available with sample pages: 0203361385